Who can perform adjuvant chemotherapy treatment for gastric cancer? A multicenter retrospective overview of the current status in Korea

Jae Seok Min, Chang Min Lee, Sung Il Choi, Kyung Won Seo, Do Joong Park, Yong Hae Baik, Myoung Won Son, Won Hyuk Choi, Sungsoo Kim, Kyung Ho Pak, Min Gyu Kim, Joong Min Park, Sang Ho Jeong, Moon Soo Lee, Sungsoo Park

Research output: Contribution to journalArticle

Abstract

Purpose: To investigate the current status of adjuvant chemotherapy (AC) regimens in Korea and the difference in efficacy of AC administered by surgical and medical oncologists in patients with stage II or III gastric cancers. Materials and Methods: We performed a retrospective observational study among 1,049 patients who underwent curative resection and received AC for stage II and III gastric cancers between February 2012 and December 2013 at 29 tertiary referral university hospitals in Korea. To minimize the influence of potential confounders on selection bias, propensity score matching (PSM) was used based on binary logistic regression analysis. The 3-year disease-free survival (DFS) rates were compared between patients who received AC administered by medical oncologists or surgical oncologists. Results: Between February 2012 and December 2013 in Korea, the most commonly prescribed AC by medical oncologists was tegafur/gimeracil/oteracil (S-1, 47.72%), followed by capecitabine with oxaliplatin (XELOX, 16.33%). After performing PSM, surgical oncologists (82.74%) completed AC as planned more often than medical oncologists (75.9%), with statistical significance (P=0.036). No difference in the 3-year DFS rates of stage II (P=0.567) or stage III (P=0.545) gastric cancer was found between the medical and surgical oncologist groups. Conclusions: S-1 monotherapy and XELOX are a main stay of AC, regardless of whether the prescribing physician is a medical or surgical oncologist. The better compliance with AC by surgical oncologists is a valid reason to advocate that surgical oncologists perform the treatment of AC for stage II or III gastric cancers.

Original languageEnglish
Pages (from-to)264-273
Number of pages10
JournalJournal of Gastric Cancer
Volume18
Issue number3
DOIs
Publication statusPublished - 2018 Sep 1

Fingerprint

Adjuvant Chemotherapy
Korea
Stomach Neoplasms
Therapeutics
Propensity Score
oxaliplatin
Disease-Free Survival
Survival Rate
Oncologists
Selection Bias
Tertiary Care Centers
Observational Studies
Retrospective Studies
Logistic Models
Regression Analysis
Physicians

Keywords

  • Adjuvant chemotherapy
  • Gastric cancer

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology
  • Cancer Research

Cite this

Who can perform adjuvant chemotherapy treatment for gastric cancer? A multicenter retrospective overview of the current status in Korea. / Min, Jae Seok; Lee, Chang Min; Choi, Sung Il; Seo, Kyung Won; Park, Do Joong; Baik, Yong Hae; Son, Myoung Won; Choi, Won Hyuk; Kim, Sungsoo; Pak, Kyung Ho; Kim, Min Gyu; Park, Joong Min; Jeong, Sang Ho; Lee, Moon Soo; Park, Sungsoo.

In: Journal of Gastric Cancer, Vol. 18, No. 3, 01.09.2018, p. 264-273.

Research output: Contribution to journalArticle

Min, JS, Lee, CM, Choi, SI, Seo, KW, Park, DJ, Baik, YH, Son, MW, Choi, WH, Kim, S, Pak, KH, Kim, MG, Park, JM, Jeong, SH, Lee, MS & Park, S 2018, 'Who can perform adjuvant chemotherapy treatment for gastric cancer? A multicenter retrospective overview of the current status in Korea', Journal of Gastric Cancer, vol. 18, no. 3, pp. 264-273. https://doi.org/10.5230/jgc.2018.18.e29
Min, Jae Seok ; Lee, Chang Min ; Choi, Sung Il ; Seo, Kyung Won ; Park, Do Joong ; Baik, Yong Hae ; Son, Myoung Won ; Choi, Won Hyuk ; Kim, Sungsoo ; Pak, Kyung Ho ; Kim, Min Gyu ; Park, Joong Min ; Jeong, Sang Ho ; Lee, Moon Soo ; Park, Sungsoo. / Who can perform adjuvant chemotherapy treatment for gastric cancer? A multicenter retrospective overview of the current status in Korea. In: Journal of Gastric Cancer. 2018 ; Vol. 18, No. 3. pp. 264-273.
@article{ae13c81c12fa4939b93e8a80e3684e68,
title = "Who can perform adjuvant chemotherapy treatment for gastric cancer? A multicenter retrospective overview of the current status in Korea",
abstract = "Purpose: To investigate the current status of adjuvant chemotherapy (AC) regimens in Korea and the difference in efficacy of AC administered by surgical and medical oncologists in patients with stage II or III gastric cancers. Materials and Methods: We performed a retrospective observational study among 1,049 patients who underwent curative resection and received AC for stage II and III gastric cancers between February 2012 and December 2013 at 29 tertiary referral university hospitals in Korea. To minimize the influence of potential confounders on selection bias, propensity score matching (PSM) was used based on binary logistic regression analysis. The 3-year disease-free survival (DFS) rates were compared between patients who received AC administered by medical oncologists or surgical oncologists. Results: Between February 2012 and December 2013 in Korea, the most commonly prescribed AC by medical oncologists was tegafur/gimeracil/oteracil (S-1, 47.72{\%}), followed by capecitabine with oxaliplatin (XELOX, 16.33{\%}). After performing PSM, surgical oncologists (82.74{\%}) completed AC as planned more often than medical oncologists (75.9{\%}), with statistical significance (P=0.036). No difference in the 3-year DFS rates of stage II (P=0.567) or stage III (P=0.545) gastric cancer was found between the medical and surgical oncologist groups. Conclusions: S-1 monotherapy and XELOX are a main stay of AC, regardless of whether the prescribing physician is a medical or surgical oncologist. The better compliance with AC by surgical oncologists is a valid reason to advocate that surgical oncologists perform the treatment of AC for stage II or III gastric cancers.",
keywords = "Adjuvant chemotherapy, Gastric cancer",
author = "Min, {Jae Seok} and Lee, {Chang Min} and Choi, {Sung Il} and Seo, {Kyung Won} and Park, {Do Joong} and Baik, {Yong Hae} and Son, {Myoung Won} and Choi, {Won Hyuk} and Sungsoo Kim and Pak, {Kyung Ho} and Kim, {Min Gyu} and Park, {Joong Min} and Jeong, {Sang Ho} and Lee, {Moon Soo} and Sungsoo Park",
year = "2018",
month = "9",
day = "1",
doi = "10.5230/jgc.2018.18.e29",
language = "English",
volume = "18",
pages = "264--273",
journal = "Journal of Gastric Cancer",
issn = "2093-582X",
publisher = "Korean Gastric Cancer Association",
number = "3",

}

TY - JOUR

T1 - Who can perform adjuvant chemotherapy treatment for gastric cancer? A multicenter retrospective overview of the current status in Korea

AU - Min, Jae Seok

AU - Lee, Chang Min

AU - Choi, Sung Il

AU - Seo, Kyung Won

AU - Park, Do Joong

AU - Baik, Yong Hae

AU - Son, Myoung Won

AU - Choi, Won Hyuk

AU - Kim, Sungsoo

AU - Pak, Kyung Ho

AU - Kim, Min Gyu

AU - Park, Joong Min

AU - Jeong, Sang Ho

AU - Lee, Moon Soo

AU - Park, Sungsoo

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Purpose: To investigate the current status of adjuvant chemotherapy (AC) regimens in Korea and the difference in efficacy of AC administered by surgical and medical oncologists in patients with stage II or III gastric cancers. Materials and Methods: We performed a retrospective observational study among 1,049 patients who underwent curative resection and received AC for stage II and III gastric cancers between February 2012 and December 2013 at 29 tertiary referral university hospitals in Korea. To minimize the influence of potential confounders on selection bias, propensity score matching (PSM) was used based on binary logistic regression analysis. The 3-year disease-free survival (DFS) rates were compared between patients who received AC administered by medical oncologists or surgical oncologists. Results: Between February 2012 and December 2013 in Korea, the most commonly prescribed AC by medical oncologists was tegafur/gimeracil/oteracil (S-1, 47.72%), followed by capecitabine with oxaliplatin (XELOX, 16.33%). After performing PSM, surgical oncologists (82.74%) completed AC as planned more often than medical oncologists (75.9%), with statistical significance (P=0.036). No difference in the 3-year DFS rates of stage II (P=0.567) or stage III (P=0.545) gastric cancer was found between the medical and surgical oncologist groups. Conclusions: S-1 monotherapy and XELOX are a main stay of AC, regardless of whether the prescribing physician is a medical or surgical oncologist. The better compliance with AC by surgical oncologists is a valid reason to advocate that surgical oncologists perform the treatment of AC for stage II or III gastric cancers.

AB - Purpose: To investigate the current status of adjuvant chemotherapy (AC) regimens in Korea and the difference in efficacy of AC administered by surgical and medical oncologists in patients with stage II or III gastric cancers. Materials and Methods: We performed a retrospective observational study among 1,049 patients who underwent curative resection and received AC for stage II and III gastric cancers between February 2012 and December 2013 at 29 tertiary referral university hospitals in Korea. To minimize the influence of potential confounders on selection bias, propensity score matching (PSM) was used based on binary logistic regression analysis. The 3-year disease-free survival (DFS) rates were compared between patients who received AC administered by medical oncologists or surgical oncologists. Results: Between February 2012 and December 2013 in Korea, the most commonly prescribed AC by medical oncologists was tegafur/gimeracil/oteracil (S-1, 47.72%), followed by capecitabine with oxaliplatin (XELOX, 16.33%). After performing PSM, surgical oncologists (82.74%) completed AC as planned more often than medical oncologists (75.9%), with statistical significance (P=0.036). No difference in the 3-year DFS rates of stage II (P=0.567) or stage III (P=0.545) gastric cancer was found between the medical and surgical oncologist groups. Conclusions: S-1 monotherapy and XELOX are a main stay of AC, regardless of whether the prescribing physician is a medical or surgical oncologist. The better compliance with AC by surgical oncologists is a valid reason to advocate that surgical oncologists perform the treatment of AC for stage II or III gastric cancers.

KW - Adjuvant chemotherapy

KW - Gastric cancer

UR - http://www.scopus.com/inward/record.url?scp=85054542019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054542019&partnerID=8YFLogxK

U2 - 10.5230/jgc.2018.18.e29

DO - 10.5230/jgc.2018.18.e29

M3 - Article

AN - SCOPUS:85054542019

VL - 18

SP - 264

EP - 273

JO - Journal of Gastric Cancer

JF - Journal of Gastric Cancer

SN - 2093-582X

IS - 3

ER -